TY - JOUR
T1 - Treatment of hypereosinophilic syndrome with imatinib mesilate
AU - Gleich, Gerald J.
AU - Leiferman, Kristin M.
AU - Pardanani, Animesh
AU - Tefferi, Ayalew
AU - Butterfield, Joseph H.
N1 - Funding Information:
We thank Glenn Burkland, John Schmale, and Ronald Steis for discussions on patients 1, 2, and 4, respectively; Sandra Dunnette for preparation of table and figure ; Cheryl Adolphson for editing the manuscript; and Linda Arneson for preparation of the manuscript. Supported in part by grants from the National Institutes of Health, AI 09728 and AI 34577, and from the Mayo Foundation. The grant providers had no role in study design, data collection, data analysis, data interpretation, or writing of the report.
PY - 2002/5/4
Y1 - 2002/5/4
N2 - Patients with hypereosinophilic syndrome show persistent eosinophilia without recognised cause. We treated five such patients with 100 mg imatinib mesilate (formerly STI-571) daily; four male patients with normal serum interleukin 5 showed complete haematological responses; a female patient who did not respond had raised serum interleukin-5 concentrations. One patient developed leucopenia after 4 days of treatment; counts returned to normal when treatment was stopped. After 1 month, eosinophilia recurred; with further treatment for 2 days, eosinophil counts again became normal. All patients who responded stopped other treatments and reduced imatinib mesilate to 200 mg per week. This drug effectively controls eosinophilia in patients with hypereosinophilic syndrome and normal interleukin-5 concentrations.
AB - Patients with hypereosinophilic syndrome show persistent eosinophilia without recognised cause. We treated five such patients with 100 mg imatinib mesilate (formerly STI-571) daily; four male patients with normal serum interleukin 5 showed complete haematological responses; a female patient who did not respond had raised serum interleukin-5 concentrations. One patient developed leucopenia after 4 days of treatment; counts returned to normal when treatment was stopped. After 1 month, eosinophilia recurred; with further treatment for 2 days, eosinophil counts again became normal. All patients who responded stopped other treatments and reduced imatinib mesilate to 200 mg per week. This drug effectively controls eosinophilia in patients with hypereosinophilic syndrome and normal interleukin-5 concentrations.
UR - http://www.scopus.com/inward/record.url?scp=0037018763&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0037018763&partnerID=8YFLogxK
U2 - 10.1016/S0140-6736(02)08505-7
DO - 10.1016/S0140-6736(02)08505-7
M3 - Article
C2 - 12047970
AN - SCOPUS:0037018763
SN - 0140-6736
VL - 359
SP - 1577
EP - 1578
JO - Lancet
JF - Lancet
IS - 9317
ER -